Related Experiment Video
Updated: Jul 11, 2026
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
Published on: November 2, 2018
A transgenic mouse model for gene therapy of rhodopsin-linked Retinitis Pigmentosa
Mary O'Reilly1, Sophia Millington-Ward, Arpad Palfi
1Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland. oreillym@tcd.ie
Abstract:
Mutational heterogeneity in genes causative of dominantly inherited disorders represents a significant barrier for development of therapies directed towards correction of the primary genetic defect. To circumvent the mutational heterogeneity present in rhodopsin- (RHO-) linked autosomal dominant Retinitis Pigmentosa (adRP), a strategy involving suppression and replacement of RHO has been adopted. RNA interference- (RNAi-) mediated suppression of RHO has been explored as has the generation of an RNAi-resistant replacement gene using the degeneracy of the genetic code. Additionally, the functional equivalence of codon-modified replacement genes has been demonstrated in a transgenic animal (RHO-M). Suppression and replacement, while exemplified by adRP, may also be relevant to many other dominantly inherited diseases with the hallmark of mutational heterogeneity.
Insights
This study introduces a novel gene therapy approach for dominant inherited disorders like Retinitis Pigmentosa. The strategy suppresses the faulty gene and replaces it with a functional, modified version, overcoming genetic mutation challenges.
Area of Science:
- Genetics
- Molecular Biology
- Ophthalmology
Background:
- Dominantly inherited disorders often feature gene mutations, hindering direct genetic defect correction.
- Rhodopsin (RHO)-linked autosomal dominant Retinitis Pigmentosa (adRP) exemplifies this challenge due to mutational heterogeneity.
Purpose of the Study:
- To develop a therapeutic strategy for mutational heterogeneity in dominant inherited diseases.
- To address RHO-linked adRP by suppressing the defective RHO gene and introducing a functional replacement.
Main Methods:
- Utilizing RNA interference (RNAi) for RHO gene suppression.
- Engineering an RNAi-resistant RHO replacement gene via codon modification.
- Demonstrating functional equivalence in a transgenic RHO-M animal model.
Main Results:
- Successful suppression of the endogenous RHO gene was achieved.
- An RNAi-resistant, functional RHO replacement gene was successfully generated.
- The codon-modified RHO gene proved functionally equivalent in vivo.
Conclusions:
- Gene suppression and replacement is a viable strategy for diseases with mutational heterogeneity.
- This approach, demonstrated in adRP, holds potential for other dominant inherited disorders.
- The RHO-M model validates the efficacy of codon-modified replacement genes.
